Nanjing Vazyme Biotech Past Earnings Performance
Past criteria checks 1/6
Nanjing Vazyme Biotech's earnings have been declining at an average annual rate of -42%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 5.5% per year. Nanjing Vazyme Biotech's return on equity is 0.6%, and it has net margins of 1.7%.
Key information
-42.0%
Earnings growth rate
-77.6%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 5.5% |
| Return on equity | 0.6% |
| Net Margin | 1.7% |
| Next Earnings Update | 29 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Nanjing Vazyme Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,403 | 24 | 731 | 307 |
| 30 Jun 24 | 1,364 | 26 | 714 | 309 |
| 31 Mar 24 | 1,285 | -15 | 703 | 324 |
| 31 Dec 23 | 1,286 | -71 | 702 | 339 |
| 30 Sep 23 | 2,133 | -232 | 843 | 373 |
| 30 Jun 23 | 2,520 | -101 | 903 | 411 |
| 31 Mar 23 | 2,896 | 112 | 917 | 410 |
| 31 Dec 22 | 3,569 | 594 | 911 | 396 |
| 30 Sep 22 | 2,885 | 878 | 730 | 352 |
| 30 Jun 22 | 2,663 | 900 | 663 | 303 |
| 31 Mar 22 | 2,302 | 773 | 587 | 263 |
| 31 Dec 21 | 1,869 | 678 | 511 | 230 |
| 30 Sep 21 | 1,715 | 767 | 432 | 188 |
| 31 Dec 20 | 1,564 | 822 | 290 | 126 |
| 31 Dec 19 | 268 | 26 | 144 | 62 |
| 31 Dec 18 | 171 | 1 | 93 | 53 |
Quality Earnings: 688105 has a large one-off gain of CN¥209.2M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 688105 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688105's earnings have declined by 42% per year over the past 5 years.
Accelerating Growth: 688105 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 688105 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Return on Equity
High ROE: 688105's Return on Equity (0.6%) is considered low.